How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Medication Risks

General health and science communication has long emphasized the importance of informed patient-provider dialogue, particularly regarding medication benefits and potential side effects. In this tradition, public health education often begins with broad wellness principles before narrowing to specific therapeutic contexts. The legacy of general health information provides a foundation for understanding how patients and clinicians navigate complex treatment decisions, weighing efficacy against possible adverse outcomes. Transitioning from this general framework, a focused concern emerges in occupational and environmental health settings: the relationship between bisphosphonate exposure, such as Fosamax, and the risk of osteonecrosis of the jaw. While the general health context addresses medication management in broad populations, occupational exposure introduces distinct considerations. Workers in healthcare, pharmaceutical manufacturing, or dental fields may encounter bisphosphonates through direct handling or environmental contact, raising questions about exposure routes and risk profiles that differ from standard patient administration. This pivot from general health literacy to occupational exposure concern does not require detailed mechanistic explanations. Instead, it acknowledges that the same medication discussed in patient education contexts may present unique challenges in workplace settings. The transition underscores the need for specialized risk communication and monitoring protocols that extend beyond typical patient counseling, reflecting the evolving scope of health information as it applies to diverse populations and exposure scenarios.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general framework of medication risk communication, this section focuses specifically on Fosamax (alendronate), a bisphosphonate approved for osteoporosis and other bone conditions, and its association with osteonecrosis of the jaw (ONJ). ONJ is a serious condition characterized by exposed, non-healing bone in the jaw, often triggered by dental procedures or infection. The following sections detail the pathophysiology, risk factors, and clinical evidence linking Fosamax to ONJ, drawing on authoritative sources including the FDA-approved labeling and peer-reviewed research.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology of how Fosamax triggers ONJ involves complex interactions between the drug's pharmacology and the unique biology of the jawbone. Fosamax, as a bisphosphonate, works by inhibiting bone resorption, which increases bone mass and reduces fracture risk in conditions like osteoporosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, this same mechanism can lead to adverse effects in the jaw. The jawbone has a high rate of bone turnover and is subject to constant mechanical stress from chewing and other oral functions. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using estrogen-deficient rat models has examined the effects of bisphosphonate (alendronate) on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These studies suggest that bisphosphonate treatment alters the mechanical and structural properties of the jawbone, potentially predisposing it to ONJ.

Risk Factors and Clinical Presentation

The mechanistic pathway linking Fosamax to ONJ involves several factors. Bisphosphonates accumulate in bone, particularly at sites of high turnover, such as the jaw. They inhibit osteoclast activity, which reduces bone remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as tooth extraction or infection. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ includes exposed bone in the jaw that does not heal within eight weeks after identification. Diagnosis is based on clinical examination and imaging. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Warnings

Regarding causation-related considerations for affected patients, the timeline between exposure to Fosamax and documented harm can be variable. The onset of ONJ symptoms may occur within days to months after starting the drug, but the condition can also develop after years of use. The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, the adequacy of warnings is a critical issue. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the warning also states that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may lead to underappreciation of the risk. The label also advises discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax can trigger ONJ through its suppression of bone remodeling in the jaw, a process that is exacerbated by local factors such as dental procedures and infection. The pathophysiology involves altered jawbone mechanical and structural properties, as evidenced by multiscale characterization studies. The risk of ONJ increases with duration of exposure, and the timeline from exposure to harm can range from days to months. Adequate warnings exist in the prescribing information, but the clinical presentation and risk factors should be carefully considered for affected patients.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits bone resorption by suppressing osteoclast activity, which reduces bone remodeling. In the jawbone, which has high turnover, this suppression impairs repair of microdamage and response to stressors like tooth extraction or infection, leading to ONJ. Studies show altered mechanical and structural properties of the jawbone after bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Duration of bisphosphonate exposure increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ develop?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months, but it may also develop after years of use. The risk increases with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.